INTRODUCTION
Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by persistent, intrusive thoughts and urges (obsessions) and repetitive, intentional behaviors (compulsions), typically, but not always, performed to reduce anxiety caused by obsessions. 1 The estimated lifetime prevalence of OCD is 1-3%, based on national surveys. 2 Individuals with OCD experience a chronic or episodic course with exacerbations that can substantially impair social and occupational functioning. 1 Since the early twentieth century, clinicians have suspected that heredity plays an important role in susceptibility to OCD. Consistent with this, several family studies have found a substantially greater prevalence of OCD (∼10-fold increase) in the first-degree relatives of probands, compared with relatives of controls. [3] [4] [5] [6] Family studies of OCD in child and adolescent probands report even greater differences in the risk of OCD in relatives of cases compared with controls, 7, 8 consistent with previous reports of increased familial loading with an early age at onset. 3, 4 The few existing studies that have examined twin concordance rates for OCD are insufficient in size to allow for accurate heritability estimates. 9 However, population-based twin studies estimate the heritability of dimensional measures of obsessivecompulsive symptoms (OCS) to be 40-50%, with a similar contribution from nonshared environment and no significant contribution from shared environment. [10] [11] [12] [13] [14] More recently, direct interrogation of the genome using genome-wide complex trait analysis (GCTA) on data from the International OCD Foundation Genetics Consortium (IOCDF-GC) genome-wide association study (GWAS) provided heritability estimates of 0.37 (s.e. = 0.07, P = 1.5 × 10 − 07 ) for OCD. In the same sample, the estimate of heritability for childhood-onset OCD (symptoms before the age of 17 years 15 ) was 0.43 (s.e. = 0.10, P = 1 × 10 − 05 ). Partitioning by minor allele frequency (MAF) suggested that the vast majority of the heritability was accounted for by single-nucleotide polymorphisms (SNPs) with MAF 40.30; little heritability was accounted for by SNPs with a MAF of o 5%. 15 To date, eight whole-genome studies of OCD or OCS have been published, including five linkage studies, [16] [17] [18] [19] [20] [21] [22] two GWASs of OCD 23, 24 and one GWAS of OCS. 25 The five linkage studies identified several chromosomal regions with suggestive evidence for linkage, [16] [17] [18] [19] [20] although there was little overlap between them and only one (1p36) met criteria for statistical significance for linkage. 16 Consistent with sample size expectations for highly polygenic traits, no individual susceptibility variants have yet been identified for OCD using these methods.
The two published GWASs of OCD were conducted by independent OCD consortia: the IOCDF-GC 24 and the OCD Collaborative Genetics Association Study (OCGAS). 23 The IOCDF-GC published the first OCD GWAS, comprising 1465 cases and 5557 ancestrymatched controls, as well as 400 complete trios, from 22 sites worldwide. 26 The top signal from the combined trio-case-control sample was rs297941 on chromosome 19p13.2, near FAIM2 (P = 4.99 × 10 − 7 ). Although no SNPs were found to be associated with OCD at a genome-wide significance level, a significant enrichment of methylation quantitative trait loci (P o 0.001) and frontal lobe expression quantitative trait loci (eQTLs; P = 0.001) were observed within the top-ranked SNPs, providing evidence, consistent with other disease reports, 27, 28 that biologically relevant associations are present within subthreshold GWAS results. The OCGAS reported a second GWAS, conducted by six research centers in the United States. 23 In this study, 1065 families (containing 1406 patients with OCD), combined with populationbased control samples (resulting in a total sample of 5061 individuals), were studied. The smallest P-value (P = 4.13 × 10 − 7 ) was detected for a SNP on chromosome 9p23, in close proximity to the protein tyrosine phosphate receptor D (PTPRD) gene. The second smallest P-value was 1.76 × 10 − 6 near the cadherin type 9 and 10 (CDH9 and CDH10) genes on chromosome 5p15.
A third GWAS, this one examining quantitative OCS, was conducted in 6931 individuals from the Netherlands Twin Registry. 25 This study identified one gene that met criteria for genome-wide significance, the myocyte enhancer factor 2B neighbor (MEF2BNB) (P = 2.56 × 10 − 8 ), on chromosome 19p13. The total SNP-based heritability for OCS in this sample was 0.14 (s.e. = 0.05, P = 0.003), and the polygenic risk score (PRS) derived from the IOCDF-GC GWAS was significantly associated with OCS, explaining 0.2% of the variance.
As is evident from the data above, although multiple regions of interest have been reported, there is currently little convergence of results to identify OCD susceptibility variants. This is likely because of genetic and phenotypic heterogeneity, and insufficient sample sizes. Thus, a logical next step is to use comparable data sets in combined analyses to increase power. Here, we report findings from combined analyses of the IOCDF-GC and OCGAS GWAS data aimed at further exploring the genetic underpinnings of OCD. We first used the genotypes of these two studies, after imputation to a common reference, to conduct a joint GWAS. We then used each individual study as a discovery sample for PRS analysis and predicted case-control status in the alternate data set to investigate the amount of phenotypic variation explained by the respective PRS. To replicate the finding that SNPs with high MAF account for the majority of the heritability in OCD, we next computed the common variation heritability of the OCGAS sample using GCTA and performed the same partitioning, as previously reported. 15 Finally, we used linkage disequilibrium (LD) score regression 29 to estimate the heritability of OCD based on the combined meta-analysis cohort.
MATERIALS AND METHODS Samples
For these analyses we used only individuals of European ancestry from the original GWAS samples, yielding 1429 cases, 5089 controls and 285 trios from IOCDF-GC and 344 cases and 1033 controls and 630 trios from OCGAS (Supplementary Table S1 ), after the addition of screened controls from the Genomic Psychiatry Cohort, 30 matched to the OCGAS cases. All cases met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition), criteria for OCD. 1 Controls from the IOCDF-GC GWAS were unscreened. Additional information on the IOCDF-GC and OCGAS samples and methods has been previously published. 23, 26 This work was approved by the relevant institutional review boards at all participating sites, and all participants provided written informed consent.
GWAS analyses
We imputed genotype-level data from the IOCDF-GC (except the Dutch samples that were imputed separately, see below), OCGAS and Genomic Psychiatry Cohort samples using IMPUTE2 (ref. 31 ) and reference haplotypes from the 1000 Genomes Project (Phase I integrated variant set release); NCBI build 37 (hg19) was constructed with SHAPEIT2. 32 We assessed genetic relatedness between samples through identity-bydescent estimation between all sample pairs using PLINK 33 Figures S1-S5 ). We conducted separate association analyses for each case-control subpopulation (IOCDF-GC European (IOEU), IOCDF-GC Ashkenazi Jewish (IOAJ), IOCDF-GC South African (IOSA), OCGAS case-control (OCCC)) and trio sample (IOCDF-GC trios (IOTR) and OCGAS trios (OCTR); as probands versus pseudo-controls). We defined 'pseudo-controls' as the non-transmitted haplotype pairs from parents to affected offspring in the trio samples.
Because of more stringent data sharing restrictions for Dutch cases, imputation and summary statistics for the Dutch cases and populationmatched controls (IODU) were calculated separately by the site investigators following the same imputation and quality control (QC) procedures. We then performed meta-analysis using the summary statistics of all case-control subpopulations (including IODU) and trio samples using METAL 34 with the inverse variance method on SNPs that passed QC in at least 500 cases and 500 controls. Results were visualized with Assocplots. 35 The top loci of meta-analysis were defined by the regions of LD pruned independent top SNPs passing predefined P-value threshold (r 2 o 0.2, 500 kb window, clump function in PLINK) and their tagged SNPs (r 2 40.2, 1000 kb window, show-tags function in PLINK) using 1KG samples of European independent founders (EUR, TSI and GBR, phase 1) as the reference panel.
PRS analysis
We conducted PRS analyses using PLINK, as previously described, 36 to test whether multiple variants of small effect jointly contribute to OCD. PRSs for subsets of the IOCDF-GC sample (IOEU) and the OCGAS sample (OCTR) (target samples) were calculated based on the SNP effect size estimated from the discovery samples, the OCGAS and European ancestry IOCDF-GC samples (excluding IOAJ), respectively. Imputed SNPs with high quality (IMPUTE2 info 40.95, MAF 40.05) and GWAS P-values passing predetermined significance thresholds (Po0.0001, 0.001, 0.01, 0.1, 0.2, 0.3, 0.4 and 0.5) in the discovery samples were extracted along with their risk alleles and odds ratios (ORs), and then LD pruned within 500 kb window at r 2 40.2 (clump function in PLINK) using 1KG samples of European independent founders (EUR, TSI and GBR, phase 1) as the reference panel.
For each significance threshold, a quantitative aggregate risk score was calculated for each individual in the target sample IOEU and OCTR, defined as the sum of the number of risk alleles present at each locus weighted by the log of the OR for that locus estimated from the discovery sample. We examined the relationship between aggregate risk score and case-control status in the target samples, IOEU and OCTR, at each significance threshold, using logistic regression controlling for population stratification. We then estimated the percentage of phenotypic variance explained by the aggregate risk score (Nagelkerke's pseudo-R 2 ).
Heritability and genetic correlations
Genetic complex trait analysis. We used GCTA v1.24 (http://cnsgenomics. com/software/gcta/) to estimate the proportion of phenotypic variance explained by directly genotyped and imputed SNPs in the OCGAS sample, as has previously been done in the IOCDF-GC sample. 15 Because of the sensitivity of GCTA to low-quality SNPs and remotely related samples, we conducted more stringent QC for these analyses by removing SNPs with Hardy-Weinberg equilibrium Po0.05 and platform effects with P o0.01 (detected by GWAS comparison of platforms among population-matched controls) and removing one member of each sample pair with pi_hat40.05. For directly genotyped and imputed SNPs respectively, this resulted in 487 459 directly genotyped and 5 843 119 imputed SNPs on 999 cases and 1064 controls. After QC, we used the GCTA software to generate a genetic relationship matrix (GRM) file that included identity-bydescent relationships calculated from genotype data. Genomic restricted maximum likelihood (GREML) analysis was conducted using the respective GRM estimated from all the SNPs and 20 principal component quantitative covariates. In order to account for the oversampling of cases, we used the OCD population prevalence (2.5%) to transform the estimate of variance explained to the liability scale. Finally, we estimated the chromosomespecific heritability and heritability partitioned by MAF for five MAF bins (0.01-0.1, 0.1-0.2, 0.2-0.3, 0.3-0.4 and 0.4-0.5).
We then combined the two largest European IOCDF-GC and OCGAS data sets (not including trios, IOAJ, IOSA or Dutch), and performed a second round of QC to remove any samples that fell outside the European genetic cluster, and one sample of any pair with a pi-hat 40.05, resulting in 1323 cases and 4938 controls. At the SNP level, we filtered the imputed SNPs based on the imputation info quality metric (info40.6), certainty (o 80%) and MAF (o 0.05) that resulted in 5 235 858 SNPs. A prevalence of 2.5% and 20 principal components were used for the GREML analysis.
LD score regression analysis. We applied the LD score regression (LDSC) method 29 to 1 159 580 imputed and directly genotyped SNPs (that overlapped with a panel of high confidence HapMap3 SNPs) measured on all 9725 (2688 cases and 7037 controls) individuals included in the OCD meta-analysis. Regression weights were calculated using the HapMap European reference sample provided by Bulik-Sullivan et al. 29 To transform from the observed heritability scale to the liability scale we used a population prevalence of 2.5%. Using LDSC, we calculated heritability, checked for residual population stratification (based on the LDSC intercept), and calculated genetic correlation between the two consortium sample collections.
RESULTS

Genome-wide association study
After data cleaning to remove samples falling outside the European genetic cluster, we had a total sample size of 2688 OCD cases and 7037 gnomically matched controls, comprising seven subsamples (Supplementary Table S1 ) that were analyzed individually and then combined by meta-analysis to provide overall P-values on 8 693 187 autosomal SNPs. We generated quantile-quantile plots of the observed versus expected log(P) values under the null hypothesis and calculated the genomic control lambda for the final sample. We observed no evidence for significant residual stratification effects (Supplementary Figure S6 ; λ = 1.028; λ 1000 = 1.007). In addition, the LDSC analysis demonstrated no evidence of residual population stratification (LDSC intercept = 1.0005; s.e. = 0.0068).
No SNP exceeded the genome-wide threshold for significance ( Figure 1 Figure S8 ) that lies wholly within GRID2 (Glutamate Ionotropic Receptor Delta Type Subunit 2). Within this haplotype there were SNPs with heterogeneity P-values of o 0.05; we conducted random-effects meta-analysis using PLINK and the findings were different. We identified that the heterogeneity came from the isolate subpopulation South African. Excluding this sample (post hoc) from the meta analysis, the ; OR= 0.84). The SNP with the third lowest P-value, rs12504244 (P = 1.6 × 10 − 6 ; OR = 1.18; CI: 1.11-1.27), on chromosome 4q12 tagged the third best haplotypic block (chr4: 55 476 381-55 580 596; 104.2 kb; Supplementary Figure S9 ) that overlies the promoter and much of the gene body of KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase).
PRS analysis
We used SNP effect sizes derived from the individual OCGAS and IOCDF-GC meta-analyses to calculate PRS and predict OCD status in individuals of European ancestry from the IOCDF-GC sample (IOEU) and in trios of European ancestry from the OCGAS sample (OCTR), respectively. As shown in Figure 2 and Supplementary Table S3, the PRS derived from meta-analysis of the European IOCDF-GC samples (excluding the IOAJ samples to avoid heterogeneity in the discovery sample) reasonably predicted casecontrol status in the OCGAS trio target sample (P = 0.003), explaining ∼ 0.9% of the phenotypic variance. Conversely, risk scores derived using the OCGAS as a discovery sample explained 0.3% of the phenotypic variance in the IOEU samples (P = 0.0009).
Heritability analyses GCTA-based heritability in the OCGAS sample alone (999 cases and 1064 controls; Table 2 ) was 0.25 (s.e. = 0.11, P = 0.0096). The GCTA heritability estimate of OCD in the combined OCGAS and IOCDF-GC European sample was also 0.25 (s.e. = 0.05; P = 0.0096). LDSC analysis yielded a heritability estimate of 0.28 (s.e. = 0.04) for the combined OCD sample (Table 2 ). When the sample was then split into its constituent parts (OCGAS and IOCDF-GC), we observed a significant genetic correlation between the two (r g = 0.83; s.e. = 0.28; P = 0.003).
In parallel with the univariate and bivariate analyses, we partitioned heritability by allele frequency in the OCGAS sample using five MAF bins as 0.01-0.1, 0.1-0.2, 0.2-0.3, 0.3-0.4 and 0.4-0.5 in the GRMEL joint analysis; results are presented in Supplementary Table S4 . As has been previously reported for the IOCDF-GC sample, 15 the largest proportion of heritability was observed in the highest frequency allele bins (MAF 40.4). Genetic architecture of OCD
DISCUSSION
We report the results of a meta-analysis of GWAS from the two published genome-wide association studies of OCD, with a sample of 2688 individuals with OCD that include both family-based and singleton cases, and 7037 controls. PRS and LDSC analyses confirm that the two samples share genetic risk factors for OCD, and are thus appropriate for combined GWAS analyses. With LDSC we observed a strong genetic correlation between the IOCDF-GC and OCGAS samples (r g = 0.83, s.e. = 0.28; P = 0.003). PRS derived from each sample significantly predicted case-control status in the other sample. Although the phenotypic variance explained was relatively small (R 2 = 0.9% for the OCGAS trios and 0.3% for the IOCDF-GC European cases and controls), they are comparable to those found for schizophrenia, using similar discovery sample sizes 37 (PGC2 SCZ GWAS, 2014).
Using GCTA, the heritability tagged by the SNPs in the OCGAS sample was slightly lower (25%) than previously observed for the IOCDF-GC sample (32%). 15 The ascertainment strategies differed in IOCDF-GC and OCGAS studies, with the former recruiting individuals, and the latter primarily families (trios) that may underestimate the heritability tagged by SNPs, as the polygenic load in family members of affected individuals is elevated in comparison with controls. 38 Joint heritability analyses of the two samples, using GCTA and LDSC, resulted in similar estimates (0.25 and 0.28, respectively), suggesting that the common variation heritability of OCD is between 25 and 30% (that is, ⩾ 50% of the total heritability than estimated by twin studies.
We also examined the allele frequency distribution of the common variation heritability of OCD. Although the confidence intervals of each allele frequency bin are large because of the limited sample sizes, the majority of the heritability (~65%) was accounted for by SNPs with high MAF (for example, 440%) in both the OCGAS sample alone and combined sample (Supplementary Table S4 ).
Although there were no genome-wide significant findings, the 53.7 kb (chr8: 128 568 359-128 622 083) haplotype block encompassing the top SNP, rs4733767 (Supplementary Figure S7) , contains 25 H3K27Ac peaks in the ENCODE/ROADMAP data, suggesting it has regulatory potential, 39 although the current release of the Genotype-Tissue Expression project (GTEx Release V6 (dbGaP Accession phs000424.v6.p1)) 40 has no eQTLs in the block. The closest genes on either side of rs4733767 (CASC8 and CASC11) are long noncoding RNAs that are thought as a class to have regulatory functions. 41 Both are only expressed at low levels in the brain in the GTEx database. The potential transcriptional consequences of genomic risk for OCD in this region are unclear, at present.
The second best haplotypic block (chr4: 93 479 275-94 230 511) lies entirely within GRID2, a gene expressing a subunit of an ionotropic glutamate receptor, and contains ∼ 300 H3K27Ac peaks. The region between~94 120 000 and 94 230 000 kb contains multiple SNPs that regulate GRID2 in both brain (www. BRAINEAC.org, intralobular white matter (n = 131)) 42 and testis (GTEx Release V6). In the latter, two of these SNPs overlap with those observed in this study (rs7684707 and rs5019028), and the OCD risk allele is predicted to increase expression. These eQTLs were not detected in brain in the GTEx study, most likely as a consequence of small sample size. GRID2 is highly expressed in the cerebellum, but is also expressed in other regions of the brain throughout the lifespan (www.BrainSpan.org), with detectable expression in the caudate, putamen, nucleus accumbens and the anterior cingulate cortex, all regions that have been implicated in OCD, 43 and is part of the glutamatergic signaling system that is thought to be important in OCD. 44 Deletions of portions of GRID2 in humans are responsible for spinocerebellar ataxia, autosomal recessive 18 (SCAR18; http://omim.org/entry/602368) that are severe when homozygous and milder when heterozygous. These observations suggest that lower GRID2, particularly in the cerebellum causes ataxia, whereas higher GRID2, especially in the non-cerebellar brain, may increase risk for OCD. The third best haplotypic block observed contains the promoter and much of the gene body of KIT. No eQTLs for KIT are found in GTEx (V6), but the haplotypic block is likely to regulate the gene, as it contains 47.7 kb 5′ to the transcription start site, and has 76 H3K27Ac peaks. KIT is expressed in multiple brain regions (BrainSpan and GTEx) and across the human lifespan, with highest expression during fetal development (BrainSpan). Allelic variants of KIT in humans have been observed in individuals with piebaldism, various leukemias and gastrointestinal stromal tumors (http://omim.org/entry/164920?search = kit&highlight = kit).
Of note, both KIT and GRID2 are regulated by transforming growth factor-β1 in rodents. [46] [47] [48] Comparison of findings in prior linkage or GWAS studies of OCD Of the signals with P-values of o 1 × 10 − 5 in this meta-analysis, two were in genomic regions that have been previously identified in genome-wide linkage studies. These include 7 SNPs on chromosome 10p15, 18 all of which are eQTLs of ASB13 (ankyrin repeat and SOCS box containing 13), in Epstein-Barr virustransformed lymphocytes, and predict high expression (GTEx Release V6). A 60.4 kb haplotypic block was seen in a linkage peak on 20p13 (ref.16 ) that encompasses the gene for RSPO4 and part of its promoter. The block contains SNPs that are eQTLs for RSPO4 in about a dozen tissues and an eQTL for SRXN1 in thyroid. As mentioned above, the number of brain samples in the V6 release is ⩽ 100, limiting the power to detect brain eQTLs. Overall, most of the eQTLs being detected at the present sample sizes in the GTEx project affect multiple tissues, and hence it is plausible that these SNPs may also be regulating the same genes in brain. Final determination of this will require more data.
Of the signals identified in the three prior OCD GWASs, [23] [24] [25] SNPs within DLGAP1, which was identified in the IOCDF-GC GWAS, represented the signal most strongly supported in this metaanalysis (best was rs9952159, P = 4.2 × 10 − 6 , OR = 1.20). Among the other genes of interest, signals in or near PTPRD, which was previously identified in the OCGAS GWAS (P = 2.4 × 10 − 4 , OR = 1.45), GRIK2 (rs116966225, P = 5.4 × 10 − 4 , − 158.5 kb and rs78014006, P = 7.2 × 10 − 3 , intronic) and FAIM2 (rs297941, P = 6.1 × 10 − 5 , 21.3 kb), were also identified in this meta-analysis, although not among the top hits. Although no signal was identified in this meta-analysis for either CDH9 or CDH10, we did identify a strong signal for a related cadherin gene CDH20 (rs77885126, P = 4.4 × 10 − 6 , OR = 1.83). It should be noted that according to a power analysis, the sample had low power to detect genome-wide significant association with a common SNP conferring an OR of ⩽ 1.2. The OCS GWAS was omitted from this study because it employed a different phenotype; that is, it used a self-report assessment tool that measured the presence of symptoms and not the diagnosis of OCD, as opposed to a clinical assessment that was based on OCD diagnostic criteria. We omitted it because of these differences in phenotypes, and the desire to not introduce additional heterogeneity into the study. The OCS GWAS identified RFXANK as a top signal; it was also identified among the top SNPs of this meta-analysis (rs11666960, P = 6.3 × 10 − 4 , OR = 0.87). Overall, the results from this meta-analysis support some of the preexisting findings generated from two previous GWASs of OCD. Among the best findings in this study are several glutamatergic system genes (that is, GRID2, DLGAP1). Evidence has implicated abnormalities in this system as part of the etiology of OCD and the most robust candidate gene study results have consistently identified genes involved in this neurotransmitter system (GRIN2B 49 and SLC1A1 (ref. 50) ). Therefore, further dissection of glutamatergic system genes along with increasing sample sizes will improve our understanding of the underlying mechanism of OCD.
As sample sizes grow and sequencing costs reduce further, we anticipate that genetic associations with OCD will become increasingly robust, and that a proportion of these currently suggestive findings will reach genome-wide significance.
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